Biotechnology · Boston, Massachusetts, United States
$23.58
-0.59% (-$0.14)2026-08-24
Smart-Money SignalNeutral · 49/100— Insiders are net sellers over 90 days (-$2.8M, 19 sales vs 9 buys)
Net Income-$55.4M
EPS$-1.73
Market Cap$1.6B
Price Performance
Historical data including institutional events
Company Profile
C
Claire Mazumdar Clemon
CEO & Executive Director
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
